anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
Injectable compositions comprise a sterile mixture of a liquid carrier, a parenterally administrable drug, and from 0.1 to 10% (by weight of the drug) of a surface active agent selected from quaternary ammonium compounds, sulphosuccinates, polyoxyethylene condensates of long chain alkanols and their sulphuric acid monoesters, alkylated phenoxyethanols, and alkylated phenoxy (polyethanols), the drug being defined as one which acts at a site protected by a complex lipid barrier layer (e.g. at the surface of nerve tissue).  Specified drugs of this type are adrenalin, nor-adrenalin, curare (i.e. tube or bamboo curare, pot curare, and gourd or calabash curare), lidocaine, serotonin and digitoxin. Preferred surface active agents are compounds of the formula: &lt;FORM:1083825/A5-A6/1&gt; where R is C1 to C18 alkyl, particularly nonyl or octyl, and n has an average value of 1 to 30, particularly 6 when R is nonyl and 9 to 10 when R is actyl.  Carriers may be buffered isotonic aqueous solutions, sesame or peanut oil, aqueous propylene glycol or N,N-dimethyl-formamide.  The compositions may be sterilised by filtration.  The surface active agent is said to enhance the activity of the drug, and the invention includes a method for such enhancement wherein the drug and surface active agent are parenterally administered to warm blooded animals excluding human beings, either simultaneously and preferably together as a composition, or separately (e.g. up to 15 minutes apart) so that the surface active agent is present in the animal body during the period of activity of the drug.  Examples are given for this method, using Triton X-100 (Registered Trade Mark) and similar compounds as the surface active agent.
1288789 Bismuth preparations W J SERFONTEIN 19 Dec 1969 [23 Dec 1968 (2)] 62062/69 Heading A5B A composition for treating peptic ulcers is a modified composition of the type represented by bismuth ammonium citrate cum pepsin (e.g. &#34;Mistura Pepsini et Bismuthi Compositum sine tinctura nucis vomical et acid hydrocyanicum&#34;) which has been modified by complex formation or conversion and which in its liquid form, comprises at least 27 mg/ml soluble bismuth derived from bismuth ammonium citrate or its equivalent, at least part of the bismuth being present as a water-soluble protein complex which, on addition of alcohol, precipitates as a thick, gelatinous precipitate which, when subjected to gel filtration at pH 9.0 on a saturated column of cross-linked dextran of a grade suitable for the separation of peptides and globular proteins in the M.U. range 4,000 to 150,000, yields two peaks of which the first includes over 10% of the said bismuth. A ligand-forming dye, e.g. cochineal, carmine, or azo-rubrium may also be present. The invention also comprises a method of preparing the bismuth-containing material by precipitation of a gelatinous precipitate from the known preparations of the type abovementioned and subjecting it to gel filtration to obtain the required material.
PURPOSE:To collect colistin, by cultivating a bacterium belonging to the genus Bacillus capable of producing the titled substance in a medium containing an inorganic phosphoric acid and nitrogen in the form of ammonia in fixed concentrations, forming and accumulating the titled substance in the culture. CONSTITUTION:A strain such as Bacillus polymyxa veriety H-3123, etc. belonging to the genus Bacillus, capable of producing colistin is cultivated in a medium containing 10&lt;-4&gt;-5X10&lt;-2&gt;g/dl calculated as an inorganic phosphoric ion of inorganic phosphate such as potassium phosphate, etc. and 0.02-0.5g/dl nitrogen in the form of ammonia such as ammonium sulfate, ammonium chloride, etc. Starch, maltose, saccharose, etc. are used as a sugar source for the main fermentation medium, the nitrogen source contains ammonium sulfate, ammonium chloride, etc., and the cultivation is carried out aerobically at 20-40 deg.C for 2-3 days. Colistin is collected from the culture by filtration, ion exchange resin treatment, etc.
FIELD: medicine. ^ SUBSTANCE: invention concerns medicine, particularly oncology, and can be applied in treating disseminated renal carcinoma (DRC). A method consists in the preliminary analysis of patient&#39;s peripheral blood for absolute concentration of CD4+CD25+Foxp3Treg phenotype cells in mm3. If the value is higher than 100 cells/mm, the patient is prescribed with Ronkoleukin combined with Cyclophosphamide for three weeks with Cyclophosphamide administered in amount 200 mg intramuscularly three times a week every second day, while Ronkoleukin - three times a week in combination with Cyclophosphamide in amount 1 mg intravenously drop-by-drop for two hours, after dissolved in 400 ml of physiologic saline or inhaled in the same dosage, after dissolved in 8-10 ml of physiologic saline. Also, for three weeks, Neovastat is introduced by 30 ml two times a day orally daily. Said therapeutic course is followed with blood analysis for absolute concentration of CD4+CD25+Foxp3Treg phenotype cells every 5 weeks, and if observing the value exceeding 100 cells/mm3, treatment is continued by the suggested regimen same scheme, and the value below 100 cells/mm3 requires the case follow-up. ^ EFFECT: method allows to improve outcome in the DRC patients, to reduce a number of side effects. ^ 5 tbl, 1 ex
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a bathing agent excellent in skin-tightening effects, slimming effects and skin care effects.  &lt;P&gt;SOLUTION: The bathing agent comprises Huang Hua Cai (yellow flower vegetable) or an extract thereof. The bathing agent further contains caffeine or a salt thereof, a bicarbonate salt or a carbonate salt. Huang Hua Cai is a general term of flowers and buds of plants originating from Hemerocallis Plicata Stepf, Hemerocallis fulva var. fluva, Hemerocallis fulva var. kwanso, Hemerocallis flava, Hemerocallis flava var. minor, and analogous plants thereof belonging to the family of Liliaceae. The compounded amount of Huang Hua Cai or an extract thereof in the whole amount of the bathing agent is preferably 0.0001-30 mass%, particularly preferably 0.0002-5 mass%, in terms of dried matter.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
PROBLEM TO BE SOLVED: To produce a rapidly soluble coating agent composition, rapidly soluble at normal temperatures in spite of a solid plasticizer contained therein, hardly separating a pigment and capable of forming a film by coating thereof on a tablet such as a medicine. SOLUTION: This rapidly soluble coating agent composition is obtained by adding and mixing a plasticizer which is a solid at normal temperatures and a pigment with a coating base and then heating the resultant mixture at the solidifying point of the plasticizer or above. The coating base is a granular hydroxypropyl methyl cellulose or methyl cellulose having 200-1000μm average grain diameter and the content of the grains having &lt;=75μm grain diameter is &lt;=30wt.%. The plasticizer is at least one selected from polyethylene glycol having 950-25000 weight-average molecular weight and blended in an amount of 5-30wt.% based on the coating base. Titanium oxide or iron oxide or both are used as the pigment and blended in an amount of 1-30wt.% based on the coating base.  An aqueous coating agent can rapidly be prepared without requiring a special dissolving apparatus and a constant color tone can always be reproduced.
What is disclosed is a software interface tool for breast cancer screening that is designed for medical professionals to view and analyze suspicious regions for hot spots and hence facilitate a determination of whether identified areas of breast tissue are cancerous. Isotherm maps are constructed at designated temperature resolution. Maps are displayed on the screen. Point &amp; click on the isotherm map can extract temperature values of pixels within the region covered by the isotherm contours. Also provided are isothermic views at different viewing angles which is advantageous for visual detection. Additional functionalities for hotspot selection, cropping, zooming, viewing at different angles, etc. are also enabled by the present software interface. The present software interface further utilizes a tumor detection method which is also disclosed herein.
The present invention belongs to the technical field of a Chinese patent medicine. At present, oral medicines for treating piles in the medicinal material market have poor effects and high relapse rate; in order to solve the problem, the present invention provides a specific oral medicine for treating piles. The present invention is composed of eight medicines such as rhubarb, heterophylly falsestarwort root, pig&#39;s bile, liquorice root, Chinese honeylocust fruit (Chinese honeylocust abnormal fruit), zheshu, common aucklandia root and gypsum. In the &#39;Chinese Medicine Dictionary&#39; and school books in high medicine colleges, the eight medicines are not used for treating piles, but the present invention integrates the medicines into a prescription for treating piles, which truly obtains special effects, and the relapse rate is very low. The present invention can be used for treating internal piles, external piles, mixed piles and piles fistulas. The medicine has the advantages of low toxicity, safety, reliability, wide medicine source, low cost and simple production technology and is suitable for extensive patients. The formula of the medicine is characterized in that the contrary medicine of the Chinese honeylocust fruit (the Chinese honeylocust abnormal fruit) can be reused. The present invention truly has the advantages of high novelty, creativity and practicability.
A method of preparing certain bis-quaternary ammonium compounds and mixtures is disclosed. The method involves contacting a tertiary amine with a suitable amount of neutralizing acid, e.g. HCl, and subsequently contacting the resulting mixture with a suitable epoxide, e.g. epichlorohydrin, at an elevated temperature and in an amount that e.g. 2-hydroypropylene-bis-1,3-(dimethyl stearyl ammonium chloride) is obtained in almost stoichiometric yields. The resulting bis-quaternary ammonium compounds can be incorporated into a hair conditioner whereby a softer feel and better control of hair is obtained. 
     The general structure for the resulting bis-quaternary ammonium compounds is as follows: ##STR1## wherein the R&#39;s are selected from the group consisting of alkyl, alkylamidoalkyl, aryalkyl, aryl, alkoxy, alkenyl, hydroxyalkyl, and carboxyalkyl and X is a negative radical from the epoxide used, e.g. epichlorohydrin.
PURPOSE:To precisely and continuously fractionate a fat-soluble physiologically active substance at a high speed by subjecting the fat-soluble physiologically active substance to fractionating operation with an organic solvent converted into a poor solvent using a high-pressure gas and extracting operation with a supercritical fluid. CONSTITUTION:A high-pressure gas such as carbon dioxide is dissolved in a solution containing a fat-soluble physiologically active substance in a natural resource such as a plant in an organic solvent (e.g. ethanol), which is then converted into a poor solvent at 10-60 deg.C under 5-80kg/cm&lt;2&gt; pressure to separate the highly polar physiologically active substance as a crystal or a concentrated liquid. Furthermore, a supercritical fluid (e.g. gaseous carbon dioxide) is mixed with the solution thereof in the organic solvent after separating a highly polar physiologically active substance and the extracting operation with the supercritical fluid is carried out at 35-100 deg.C under 100-500kg/cm&lt;2&gt; pressure to separate the supercritical fluid phase containing a low polar physiologically active substance dissolved therein and the organic solvent phase containing a medium polar physiologically active substance dissolved therein. Thereby, the cost is remarkably reduced and the solution containing the fat-soluble physiologically active substance in the organic solvent is continuously fractionated.
PROBLEM TO BE SOLVED: To obtain the subject medicine containing a specific imidazole derivative as an active ingredient, having a mesangium cell proliferation-inhibiting action and an extracellular substrate production stimulation-inhibiting action and useful for preventing and treating the glomerular diseases. SOLUTION: This medicine for preventing and treating glomerular diseases contains an imidazole derivative of formula I [either one of A and B is a group of formula II (R&lt;1&gt; is H, a halogen, hydroxyl group, a lower alkyl, etc.; R&lt;2&gt; , R&lt;3&gt; are each H, a halogen, a lower alkyl, an aralkyloxy, etc.; R&lt;4&gt; , R&lt;5&gt; are each H, a 1-3C alkyl), and the other is carbamoyl] or its pharmacologically acceptable salt as an active ingredient. The compound of formula I includes (E)-5(4)-(3,4,5- trimethoxycinnamoylamino)imidazole-4(5)-carboxamide. The compound of formula I is obtained by reacting a cinnamic acid derivative or its reactive functional derivative such as its acid halide with an aminoimidazole derivative of formula IV (either one of P and Q is amino, and the other is carbamoyl).
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a safe and effective recombinant acari allergen without containing an anaphylaxis-inducing impurity as a treating and diagnosing agent of canine acari allergy disease.  &lt;P&gt;SOLUTION: This protein is provided by containing the following recombinant protein of (a) or (b). (a) A protein consisting of a specific disclosed amino acid sequence. (b) A protein containing an amino acid sequence obtained by deleting, substituting or adding one or several amino acids in the above specific amino acid sequence and having an acari allergen activity. The above acari allergen, its fragment or a fused protein with another protein is useful as the treating or diagnosing agent of the acari allergic disease, and the antibodies of them are useful for measuring the acari allergen.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
The invention discloses an auxiliary diagnosis and doctor advice success tracking system for sleep disorder. The system comprises a physiological sign data collection device, a patient end operation device and a server. The server includes a network communication interface, an application program interface module, an analysis data module, a database module and an order module. Through the physiological sign data from the patient end operation device, the reply data of the corresponding questionnaire and the patient log are analyzed by the doctor&#39;s advice module, doctors can know the instant condition of the patient and the effect of executing the doctor&#39;s advice. If the effect is out of the best, the auxiliary treatment course of self-healing of other self-discipline learning of the patient can be provided. The invention effectively strengthens the doctor-patient interaction and can strengthen the diagnosis and treatment of sleep disorder.
The invention is intended for identifying changes in nucleotide terminals of the DNA of the telomeric regions of chromosomes occurring during the course of the cell cycle. The method is based on a novel approach without the use of ligation. The method comprises the steps of first extracting genome DNA, isolating a fraction of single-stranded G overhangs of telomeric DNA and subsequently amplifying the minus chain of said G overhangs with duplex-specific analysis. The amplification steps comprise modification of the 3&#39; ends of telomeric G overhangs with the aid of a terminal deoxynucleotidyl transferase and are performed using a set of primers in sequences SEQ ID NO:1-5. The duplex-specific analysis is based on hybridization of the minus chains of the overhangs with a set of specific fluorescent probes (SEQ ID NO:6-11), which correspond to six possible variants of the nucleotide terminals of the G chain of human telomeric DNA. The degree of buildup of the probes in the presence of a duplex-specific nuclease enzyme is used as the criterion for the presence of a corresponding variant of a nucleotide terminal of DNA and as a measure of the quantitative content thereof. The profiles obtained for the percentage content of terminal triplets of the G chain of telomeric DNA are used as proliferative markers indicating the degree of activation of cell division and determining the duration of the cell cycle. The invention makes it possible to increase sensitivity and accuracy in the quantitive analysis of terminal nucleotides in comparison with procedures based on ligation. The method makes it possible to produce diagnostic results in immunology, oncology, organ transplantation, cosmetology, dermatology, gerontology, cell bioengineering and other fields interested in the assessment of the proliferative status of cells and procedures for the targeted regulation thereof.
Automated systems and methods for creating and obtaining devices, including biomedical implants. Systems can have a surgeon&#39;s device, an automated platform, and a server. The surgeon&#39;s device can send a request for a template of a biomedical implant, and can access tools to edit the template. The automated platform can receive the edited template, and can generate a response. The response can include translating the edited template into a design for a biomedical implant. The response can further include generating a notice if the edited template falls outside of an acceptable range, or if the edited template is similar to the design of a standard biomedical implant. There can also be provided a manufacturing facility that can manufacture the implant and send the implant to the surgeon.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an MU-1 hematopoietin receptor as a new protein member of a mammalian cytokine receptor family.  &lt;P&gt;SOLUTION: A polynucleotide encoding a superfamily chain and fragments thereof is provided. An MU-1 protein and a method for producing the same are also provided. Besides, an antibody specifically reactive to the protein is provided. Further, uses of the protein in medical treatments are provided.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a siltstone-containing composition and soap using the same, and to provide a method for producing them.  &lt;P&gt;SOLUTION: The siltstone-containing composition 1 or 4 comprises siltstone fine particles 2 and a fermented material 3. The fermented material 3 is obtained by fermenting a mixture of a saccharide, leaves of one or more kinds of plants and bacteria. The bacteria may be anaerobic or aerobic bacteria or both anaerobic and aerobic bacteria. The soap 10 is obtained by using a siltstone-containing composition. The siltstone-containing composition 1 or 4 and the soap 10 using the same are produced from a naturally occurring material and provides no environmental loading. The siltstone-containing composition 1 or 4 and the soap 10 are produced at low costs.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
&lt;P&gt;PROBLEM TO BE SOLVED: To improve the alkali resistance of a Prussian blue comprising a blue pigment which tends to change in color or fade in an alkaline solution, to thereby provide a new surface-treated Prussian blue coated powder having better color forming properties (higher chromaticity) than those of conventional Prussian blue coated powders.  &lt;P&gt;SOLUTION: A Prussian blue coated powder is treated with one or both of an α-oxycarboxylic acid and a film-forming substance. In the preferred embodiment, an α-oxycarboxylic acid and a film-forming substance are bonded to or adsorbed on the surface of a Prussian blue coated powder. An example of a base material that can be used for the Prussian blue coated powder is a clay mineral or the like, or a composite material obtained by coating a clay mineral or the like with e.g. a metal oxide. It is desirable to use a pearlescent pigment in particular as the base material.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
PURPOSE: To provide an unstimulant oral compsn. having high foaming property by compounding an effective amt. of highly purified sodium lauryl sulfoacetate surfactant. CONSTITUTION: This oral compsn. contains an effective amt. of purified sodium lauryl sulfoacetate prepared in such a manner that the proportion of sodium salt except for dodecylsulfoacetate as an impurity is controlled in &lt;18 wt.%, and the compsn. has high foaming property, and is not stimulating. The purified sodium lauryl sulfoacetate is preferably compounded by about 0.5 to 5.0 wt.%. To enhance the foaming power and unstimulating property of the surfactant, a nonionic or amphoteric compd. is preferably compounded. As for the nonionic compd., for example, polyoxy-ethylene monoester of sorbitol is used, and as for the amphoteric compd. for example, cocoamido propylbetaine can be used. Further, a nonionic antimicrobial agent may be compounded by about 0.05 to 1%.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a new anti-allergic agent obtained by using a readily available natural resource having slight disturbance to a plant individual.  &lt;P&gt;SOLUTION: The anti-allergic agent comprises an extract of Daemonorops draco resin as an active ingredient. The phenol derivative is selected from compounds of figures being products separated from the extract. A preferable extraction solvent is an alcohol, an acetic acid ester, a ketone, an alkane or their mixture. The separation of the compounds is carried out by a silica gel column chromatography (SigelCC).  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
PURPOSE:To obtain the subject new water-soluble and stable compound, having strong absorptivity for ultraviolet rays in a long wavelength region and further inhibiting activity against tyrosinase and useful as a skin external preparation, etc., in the cosmetic field due to its safety for human bodies. CONSTITUTION:The objective biopterin glycoside of the formula. This compound is obtained by culturing algae, belonging to the genus Oscillatoria or Phormidium and having the ability to produce the biopterin glycoside [e.g. Oscillatoria sp. NKBG91600 (FERM P-12897) or Phormidium sp. NKBG060101 (FERM P-12896)] in a nutrient culture medium usually under aerobic conditions and then collecting the produced compound from the resultant culture. The culture is preferably carried out at about 30 deg.C for 5-8 days while being irradiated with light under conditions of 50-100muEinsteins/m&lt;2&gt;/sec. Furthermore, the objective compound is preferably collected from the culture by a method for subjecting the microbial cell separated from the culture to lysis and extracting the substance with methanol, etc.
The complete nucleotide sequence of the pertussis toxin gene and the deduced amino acid sequences of the individual subunits have been determined. All five subunits are coded by closely linked cistrons and possibly expressed through a polycistronic mRNA, since a promotor-like structure was found in the 5&#39; flanking region. The order of the cistrons is S1, S2, S3, S4, S5, and S3. All subunits contain signal peptides of variable length. The calculated molecular weights of the mature subunits are 25,024 for S1, 21,924 for S2, 21,873 for S3, 12,058 for S4 and 11,013 for S5. All subunits contain signal peptides of variable length. Subunits S2 and S3 share 70% amino acid homology and 75% nucleotide homology. Subunit S1 contains two regions of eight amino acids homologous to analogous regions in the A subunit of both cholera and E. coli heat labile toxins. Functional domains in relation to the primary structure and the development of a safer, new generation vaccine against whooping cough are presented.